
Margin pivot and US consolidation: Aurobindo targets 21% EBITDA in FY27
margin recovery · US expansion · Lannett integration

hospitals · healthcare · margin compression

pharmaceuticals · us generics · revenue growth

pharmaceuticals · api · revenue rebound

specialty pharma · margin compression · us generics decline

pharma · us generics · exceptional gain

life sciences commercialization · pharma outsourcing · healthcare

api · pharma · margin expansion

pharma · jb pharma merger · acquisition-led growth

hospitals · healthcare · revenue growth

hospitals · healthcare services · revenue growth

pharma · domestic formulations · margin expansion

pharma · branded generics · us generics

api manufacturing · subsidiary consolidation · margin dilution

animal health vaccines · poultry growth · one-off gain

cdmo growth · consolidated net loss · revenue beats street

cro cdmo · contract research · librela destocking

pharmaceuticals · margin expansion · share buyback

pharmaceuticals · swing to loss · margin compression

CRO · contract-research · pharma-services

pharmaceuticals · andas · regulated markets

merger integration · organic growth · EBITDA margins

Q1FY27 · revenue-growth · margin-track

pharma · us generics slowdown · lenalidomide roll-off

specialty drugs · Organon acquisition · margin expansion